To inform public health measures to control the novel coronavirus outbreak, the U.K. has launched the COVID-19 Genomics UK Consortium to track viral spread and evolution via genome sequencing of COVID-19 samples. The group, with...

It makes sense that CRISPR-Cas13 would enter the limelight during the COVID-19 crisis, given that the SARS-CoV-2 is an RNA virus, and this Cas enzyme targets RNA. With diagnostics one of the most critical components...

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...

Technologies highlighted at a NCATS-FDA AAV manufacturing workshop could ramp up the production and durability of gene therapies, but questions remain about who will test drive these innovations and where the next wave of them...

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...

Insilico Medicine Inc. became the second AI company this week to contribute the speed of its platform to biopharma’s mass mobilization against the 2019-nCoV crisis. As the debate continues about whether AI can transform medicinal...

Karolinska, Pasteur and UCSD researchers have developed a cellular fluorescence assay that can efficiently screen for potent transcription factor allosteric modulators during lead identification. Unlike compounds that work by binding targets’ active sites, allosteric modulators...

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue. The results, which...

With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its IP position around an alternative CRISPR enzyme and expanding its gene editing capabilities beyond diagnostics into a range...

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply. At least seven manufacturing deals and site...

The first set of preclinical data from Kintai’s microbiome-derived small molecule platform supports the idea that manipulating the enteric signaling network with small molecules is one way to tap into the microbiome’s links to human...

Two manufacturing deals Tuesday underscore manufacturing's vital role in the development of next-generation gene and cell therapies. The first, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf, will combine the partners' scalable technologies...

Matthew Disney is attacking triple-negative breast cancer again with the latest iteration of his RNA-binding small molecule technology, which marries the concept with targeted RNA degradation to eliminate disease-causing RNA segments. In a paper published...

A decision at the European Patent Office has confirmed that the CRISPR IP landscape is going to look much different in Europe than it does in the U.S., contributing to the growing complexity of global...

BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to solve some of the biggest challenges of bringing CAR T cells to solid tumors. It believes that together,...